Understanding the Structure of a PBRER

Introduction

At first glance, the structure of a Periodic Benefit-Risk Evaluation Report (PBRER) may appear to be a collection of independent regulatory sections arranged according to a predefined template. New aggregate report authors often approach the document in this way, completing each section sequentially before progressing to the next. Although this approach may produce a technically complete report, it does not necessarily result in a coherent scientific assessment.

The structure described within ICH E2C(R2) has been developed to support scientific reasoning rather than administrative convenience. Each major section contributes information required to understand the medicinal product, evaluate newly available evidence and determine whether the overall benefit-risk balance has changed during the reporting interval.

Consequently, the report should be read as a continuous scientific argument rather than as a series of unrelated chapters. Earlier sections establish the context within which later evidence is interpreted. Middle sections evaluate the evidence itself. The final sections integrate that evidence into an overall benefit-risk assessment and describe any resulting conclusions or proposed regulatory actions.

Understanding this progression helps authors appreciate why apparently simple descriptive sections remain important even though they contain relatively little scientific interpretation. Information presented early in the report frequently provides the context required for later medical evaluation.

The Logic Behind the PBRER Structure

The sequence of sections within the PBRER broadly follows the same approach used during clinical reasoning.

The report begins by establishing the regulatory and product context. It then describes important developments occurring during the reporting period before progressively evaluating cumulative safety information, benefit information and the overall benefit-risk balance.

Only after all relevant evidence has been examined does the report present its integrated conclusions.

This logical progression allows regulatory assessors to understand not only what conclusions have been reached but also how those conclusions have been derived.

Writing Tip

Think of the PBRER as a scientific investigation. The report first establishes the background, then presents the evidence, interprets the findings and finally reaches conclusions supported by that evidence.

Major Groups of Sections

Although individual report templates contain numerous sections, they can be understood more easily by grouping them according to their scientific purpose.

Administrative and Regulatory Context

These sections establish the regulatory background for the report and describe changes that may influence interpretation of subsequent discussions.

Examples include worldwide marketing authorisation status, regulatory actions and changes to reference safety information.

These sections are primarily descriptive but provide important context for the remainder of the report.

Exposure and Safety Data

The next group of sections describes cumulative exposure together with important safety information collected during the reporting interval.

Rather than reaching conclusions immediately, these sections establish the factual basis upon which later scientific evaluation is performed.

Exposure data are particularly important because interpretation of adverse event reporting depends upon understanding the extent and characteristics of patient exposure.

Scientific Evaluation

These sections represent the scientific core of the PBRER.

Here, the author evaluates signals, identified risks, potential risks, benefit information and other evidence contributing to understanding of the medicinal product.

Unlike earlier descriptive sections, these chapters require substantial medical judgement.

Scientific interpretation rather than description becomes the principal objective.

Integrated Benefit-Risk Assessment

The final scientific sections bring together all preceding discussions into a single cumulative assessment.

Rather than introducing new information, these sections explain how previously discussed evidence influences the overall benefit-risk balance and whether any regulatory action should be considered.

The quality of these sections depends directly upon the quality and consistency of the discussions that precede them.